Research Use Only. KIRhub outputs are computational research artifacts. They are not validated for clinical decision-making, diagnosis, or treatment.

← Cohorts · bladder-landscape@3

DRR168556

—

d09081b2-9f06-54db-9566-8f4a0a8f5def

Score in workbench →

Clinical attributes

From the source cohort, normalized into canonical keys plus the project's native columns.

cancer_type
—
cancer_type_detailed
—
subtype
—
sex
Male

GSVA pathway preview (50 Hallmark scores)

MeasuredDerivedReference

Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.

Top 10 elevated

  • CHOLESTEROL_HOMEOSTASIS+0.340
  • PROTEIN_SECRETION+0.240
  • EPITHELIAL_MESENCHYMAL_TRANSITION+0.220
  • UNFOLDED_PROTEIN_RESPONSE+0.200
  • KRAS_SIGNALING_DN+0.160
  • MTORC1_SIGNALING+0.130
  • ADIPOGENESIS+0.120
  • PEROXISOME+0.110
  • UV_RESPONSE_UP+0.100
  • ESTROGEN_RESPONSE_LATE+0.090

Top 10 suppressed

  • INTERFERON_ALPHA_RESPONSE-0.520
  • INTERFERON_GAMMA_RESPONSE-0.370
  • MITOTIC_SPINDLE-0.320
  • ANGIOGENESIS-0.280
  • PI3K_AKT_MTOR_SIGNALING-0.270
  • IL6_JAK_STAT3_SIGNALING-0.230
  • WNT_BETA_CATENIN_SIGNALING-0.220
  • P53_PATHWAY-0.180
  • NOTCH_SIGNALING-0.160
  • APICAL_SURFACE-0.150

Patient twins — nearest pathway neighbors

MeasuredDerived

10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.

9 twins match this tumor's tissue · 1 come from a different tissue of origin

#SampleCancer typeSubtypecos similarity
1SRR8518204
breast-umap@18
—F0.681
2SRR8518189
breast-umap@18
—F0.647
33af1ff76-660f-4dff-822d-cbc90999d3ff
melanoma-umap@29
——0.643
4SRR8518238
breast-umap@18
—C0.643
5SRR8518241
breast-umap@18
—F0.638
660703_S134
lung-landscapes@6
—cohortA10.637
7GSM5359440
bladder-landscape@3
——0.631
8SRR1471817
brain-umap@2
GTEX—0.629
9SRR8518414
breast-umap@18
—C0.627
10MBCProject_0755_T1_RNA
breast-umap@18
—B0.627

Per-pathway drug coverage

ModeledCalibratedDerived

For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.

0 of 22 elevated pathways have at least one drug that meaningfully reverses them.

Pathway (elevated)tumor scoreBest drugreversal magnitude
CHOLESTEROL_HOMEOSTASIS0.340Remibrutinib— uncovered
PROTEIN_SECRETION0.240Remibrutinib— uncovered
EPITHELIAL_MESENCHYMAL_TRANSITION0.220Inavolisib— uncovered
UNFOLDED_PROTEIN_RESPONSE0.200Idelalisib— uncovered
KRAS_SIGNALING_DN0.160Remibrutinib— uncovered
MTORC1_SIGNALING0.130Inavolisib— uncovered
ADIPOGENESIS0.120Inavolisib— uncovered
PEROXISOME0.110Idelalisib— uncovered
UV_RESPONSE_UP0.100Idelalisib— uncovered
ESTROGEN_RESPONSE_LATE0.090Idelalisib— uncovered
PANCREAS_BETA_CELLS0.090Cobimetinib— uncovered
REACTIVE_OXYGEN_SPECIES_PATHWAY0.090Inavolisib— uncovered
XENOBIOTIC_METABOLISM0.090Inavolisib— uncovered
BILE_ACID_METABOLISM0.080Inavolisib— uncovered
OXIDATIVE_PHOSPHORYLATION0.080Remibrutinib— uncovered
COAGULATION0.070Binimetinib— uncovered
APICAL_JUNCTION0.060Inavolisib— uncovered
MYC_TARGETS_V10.050Inavolisib— uncovered
ANDROGEN_RESPONSE0.030Inavolisib— uncovered
ESTROGEN_RESPONSE_EARLY0.020Inavolisib— uncovered